Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7962)	11/17/2000 12:06:16 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

Cytogen Corp. (CYTO) said researchers plan later this month to present data on the company's ProstaScint, an imaging agent used to help detect metastatic prostate cancer. In a press release Thursday, the company said in one study researchers found improved treatment outcomes in prostate cancer patients who were imaged with ProstaScint prior to selection of treatment. The study showed a 92% "successful outcome" in the ProstaScint group, compared with a 70% success rate in the control group. Researchers said ProstaScint can provide added information to physicians who are making a decision about a patient's treatment. Another study compared the rate of detection of prostate cancer metastases by ProstaScint and by bone scan. Researchers found prostate cancer a greater number of times using ProstaScint than they did when using bone scans. Researchers called the findings statistically significant. Shares of Cytogen recently traded at $4.25, down 19 cents, or 4.2%, on Nasdaq volume of 675,000 shares. Average daily volume is 724,970 shares. Cytogen is a biopharmaceutical company. from yesterday's WSJ Jim